 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Clovis Pulls Plug on Personalized Cancer Drug after Trial Shows No Benefit for Drug or Marker
November 14, 2012
Clovis Pulls Plug on Personalized Cancer Drug after Trial Shows No Benefit for Drug or Marker
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Clovis on Track to Unveil Data on New Personalized Pancreatic Cancer Treatment Option by Year End
October 10, 2012 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Genentech Seeking to Expand Tarceva into First-Line Setting in EGFR-Mutated NSCLC Patients
June 8, 2011 / Pharmacogenomics Reporter - Roche, BMS Hope to Improve Outcomes in BRAF-Mutated Melanoma Patients with Dual Treatment Regimen
June 8, 2011 / Pharmacogenomics Reporter - Pfizer's PGx NSCLC Drug Yields Promising PFS Results; More Research Needed to Map Disease Mechanism
June 8, 2011 / Pharmacogenomics Reporter